ERBB2 and gastric cancer: Also, several pan-HER TKIs like Tucatinib showing already efficacy in extensively pretreated HER2+ breast cancer patients and has received market authorization for this indication in combination with Trastuzumab and Capecitabine [44] or Neratinib, which was investigated in in vitro experiments using gastric cancer cell lines [45].